Atlas Trials

An Open-label, Single Center Study Evaluating the Safety and Efficacy of Roflumilast Foam 0.3% in Subjects With Cutaneous Adverse Events Due to Checkpoint Inhibitors

Clinical trial NCT07639840 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07639840
Sponsor
Massachusetts General Hospital
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Immune-related Dermatitis
Start date
2026-08-01
Primary completion
2027-08-01
Enrollment
20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.